Delayed Cardiomyopathy in Dystrophin Deficient mdx Mice Relies on Intrinsic Glutathione Resource

Autor: Marie-Claude Bourin, Magali Perier, Christophe Meune, Françoise Pecker, Karim Wahbi, Catherine Pavoine, Lara Khouzami, Thibaud Damy, Christo Christov, Brigitte Escoubet, Philippe Caramelle
Rok vydání: 2010
Předmět:
Adult
Male
musculoskeletal diseases
congenital
hereditary
and neonatal diseases and abnormalities

medicine.medical_specialty
mdx mouse
Ratón
Duchenne muscular dystrophy
Cardiomyopathy
030204 cardiovascular system & hematology
medicine.disease_cause
Statistics
Nonparametric

Pathology and Forensic Medicine
Dystrophin
Pathogenesis
Mice
03 medical and health sciences
chemistry.chemical_compound
0302 clinical medicine
Internal medicine
medicine
Animals
Humans
030304 developmental biology
Mice
Knockout

Analysis of Variance
0303 health sciences
biology
Reverse Transcriptase Polymerase Chain Reaction
Myocardium
Heart
Glutathione
medicine.disease
Immunohistochemistry
Muscular Dystrophy
Duchenne

Endocrinology
chemistry
Echocardiography
biology.protein
Cardiomyopathies
Oxidative stress
Regular Articles
Zdroj: The American Journal of Pathology. 177:1356-1364
ISSN: 0002-9440
DOI: 10.2353/ajpath.2010.090479
Popis: Oxidative stress contributes to the pathogenesis of Duchenne muscular dystrophy (DMD). Although they have been a model for DMD, mdx mice exhibit slowly developing cardiomyopathy. We hypothesized that disease process was delayed owing to the development of an adaptive mechanism against oxidative stress, involving glutathione synthesis. At 15 to 20 weeks of age, mdx mice displayed a 33% increase in blood glutathione levels compared with age-matched C57BL/6 mice. In contrast, cardiac glutathione content was similar in mdx and C57BL/6 mice as a result of the balanced increased expression of glutamate cysteine ligase catalytic and regulatory subunits ensuring glutathione synthesis in the mdx mouse heart, as well as increased glutathione peroxidase-1 using glutathione. Oral administration from 10 weeks of age of the glutamate cysteine ligase inhibitor, l-buthionine(S,R)-sulfoximine (BSO, 5 mmol/L), led to a 33% and 50% drop in blood and cardiac glutathione, respectively, in 15- to 20-week-old mdx mice. Moreover, 20-week-old BSO-treated mdx mice displayed left ventricular hypertrophy associated with diastolic dysfunction, discontinuities in beta-dystroglycan expression, micronecrosis and microangiopathic injuries. Examination of the glutathione status in four DMD patients showed that three displayed systemic glutathione deficiency as well. In conclusion, low glutathione resource hastens the onset of cardiomyopathy linked to a defect in dystrophin in mdx mice. This is relevant to the glutathione deficiency that DMD patients may suffer.
Databáze: OpenAIRE